Stay updated with breaking news from Andreas Jungfer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
12.05.2022 HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor | HRX | Liver | Liverregeneration | MKK4 |
27.04.2022 MIG Capital continues to grow after excellent financial year 2021 | Biontech | Creative Balloons | Hemovent
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
TUBINGEN, GERMANY / ACCESSWIRE / March 30, 2022 / HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced
Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF")